Neogenomics Inc reports results for the quarter ended March 31 - Earnings Summary

NeoGenomics

29/04/2025 14:32

Neogenomics Inc NEO.OQ reported quarterly breakeven results​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -2 cents.  The mean expectation of fifteen analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents to 3 cents per share.

Revenue rose 7.5% to $168.04 million from a year ago; analysts expected $170.96 million.

Neogenomics Inc's reported EPS for the quarter was a loss of 20 cents​.

The company reported a quarterly loss of $25.92 million.

Neogenomics Inc shares had risen by 5.1% this quarter and lost 39.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 173.9% in the last three months.​

In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Neogenomics Inc is $17.50

This summary was machine generated from LSEG data April 29 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.01
0.00
Beat
Dec. 31 2024
0.03
0.04
Beat
Sep. 30 2024
0.01
0.05
Beat
Jun. 30 2024
0.00
0.03
Beat